Nevertheless, anti-IL-1 therapy was recommended in RA patients with type 2 diabetes in the TRACK (Treatment of Rheumatoid Arthritis and Comorbidities with Kineret) study as anakinra as it was as efficacious as TNF inhibitors, and enabled a decrease in antidiabetic and glucocorticoid therapies which was not observed in patients treated with TNF inhibitors [123]. This evidence concerns the gene IL1A and type 2 diabetes mellitus.